Ameritas Investment Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,360
| Closed | -$241K | – | 3129 |
|
|
2023
Q2 | $241K | Buy |
2,360
+207
| +10% | +$19.6K | 0.01% | 1021 |
|
|
2023
Q1 | $196K | Hold |
2,153
| – | – | 0.01% | 1113 |
|
|
2022
Q4 | $90.3K | Hold |
2,153
| – | – | ﹤0.01% | 1667 |
|
|
2022
Q3 | $54K | Hold |
2,153
| – | – | ﹤0.01% | 1926 |
|
|
2022
Q2 | $65K | Hold |
2,153
| – | – | ﹤0.01% | 1825 |
|
|
2022
Q1 | $71K | Hold |
2,153
| – | – | ﹤0.01% | 1852 |
|
|
2021
Q4 | $57K | Hold |
2,153
| – | – | ﹤0.01% | 2057 |
|
|
2021
Q3 | $217K | Hold |
2,153
| – | – | 0.01% | 1146 |
|
|
2021
Q2 | $305K | Buy |
+2,153
| New | +$243K | 0.01% | 960 |
|
|
2020
Q2 | – | Sell |
-1,987
| Closed | -$287K | – | 3166 |
|
|
2020
Q1 | $287K | Buy |
1,987
+101
| +5% | +$19.5K | 0.02% | 794 |
|
|
2019
Q4 | $386K | Buy |
1,886
+174
| +10% | +$31.7K | 0.02% | 815 |
|
|
2019
Q3 | $137K | Hold |
1,712
| – | – | 0.01% | 1279 |
|
|
2019
Q2 | $162K | Buy |
1,712
+189
| +12% | +$16.3K | 0.01% | 1183 |
|
|
2019
Q1 | $130K | Hold |
1,523
| – | – | 0.01% | 1312 |
|
|
2018
Q4 | $85K | Hold |
1,523
| – | – | ﹤0.01% | 1498 |
|
|
2018
Q3 | $125K | Buy |
1,523
+213
| +16% | +$15K | 0.01% | 1396 |
|
|
2018
Q2 | $46K | Buy |
1,310
+563
| +75% | +$17.1K | ﹤0.01% | 2041 |
|
|
2018
Q1 | $15K | Hold |
747
| – | – | ﹤0.01% | 2575 |
|
|
2017
Q4 | $21K | Hold |
747
| – | – | ﹤0.01% | 2416 |
|
|
2017
Q3 | $22K | Hold |
747
| – | – | ﹤0.01% | 2378 |
|
|
2017
Q2 | $24K | Buy |
747
+304
| +69% | +$7.47K | ﹤0.01% | 2362 |
|
|
2017
Q1 | $10K | Buy |
+443
| New | +$10.9K | ﹤0.01% | 2705 |
|
Other funds holding RETA
Ameritas Investment Partners's RETA Position: Q3 2023 in Review
Ameritas Investment Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,360 shares — an estimated $241K sold.
Ameritas Investment Partners first reported a position in RETA in Q1 2017 and held it in 22 quarters. The position peaked at $386K in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Ameritas Investment Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Ameritas Investment Partners sold 2,360 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $241K.
- Ameritas Investment Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2017 and held it in 22 quarters.
- Ameritas Investment Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $386K in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Ameritas Investment Partners's 13F filing for Q3 2023, filed 13 Nov 2023.